A Phase 4 interventional study of Buprenorphine/Naloxone in Post-operative Pain, sponsored by Massachusetts General Hospital. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.
Sponsored by Massachusetts General Hospital · Phase 4, Interventional, and Treatment
A randomized clinical study evaluating the effect of buprenorphine/naloxone (bup/nx) sublingual film on postoperative pain management in opioid-tolerant patients.
5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.
Browse Pain, Postoperative studies →Massachusetts General Hospital is the lead sponsor of 2,536 studies on the registry; 446 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 161 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Subjects will take a maximum dose of 4 mg buprenorphine and 1 mg naloxone with concurrent administration of other intravenous or oral opioids needed.
Drug: Buprenorphine/Naloxone
Subjects will take conventional intravenous or oral opioid management.
Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for the length of their hospital stay, at least 6 days.
Also known as: Suboxone
Postoperative Pain Scores
To examine changes in pain scores daily from the day of surgery to the hospital discharge day.
Time frame: through study completion, an average of 6 days
Postoperative Opioid Consumption
To compare opioid consumption after surgery between the buprenorphine/naloxone group and the standard medication regiment group.
Time frame: through study completion, an average of 6 days
Length of Hospital Stay
To compare the length of hospital stay after surgery between the buprenorphine/naloxone group and the standard medication regiment group.
Time frame: through study completion, an average of 6 days
Plan to share: Yes — Deidentified data may be shared with other researchers in the future.
This study is withdrawn, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital